Organization Overview
Timeline
Active Ingredients
Indications
Clinical Trials
Targets and Mechanisms
Alternative names
dolutegravir (tivicay) (2 trials)
emtricitabine (emtriva) (2 trials)
isoniazid (nydrazid) (1 trial)
mrna-1273 (Spikevax) (1 trial)
rifapentine (priftin) (1 trial)
tenofovir (viread) (6 trials)
aluminum hydroxide (Gaviscon) (1 trial)
alvac-hiv vaccine (1 trial)
as01 (1 trial)
bictegravir (Biktarvy) (1 trial)
bivalent subtype c gp120 (2 trials)
cabotegravir (Vocabria) (1 trial)
desflurane (suprane) (1 trial)
dna-hiv-pt123 (1 trial)
mf59 (1 trial)
moxifloxacin (avelox) (1 trial)
tenofovir alafenamide (genvoya) (2 trials)
elvitegravir (vitekta) (1 trial)
lactobacillus crispatus (1 trial)
lc106 (1 trial)
metronidazole (flagyl) (1 trial)
pgdm1400 (1 trial)
pgt121 (1 trial)
vrc07-523ls (1 trial)
efavirenz (sustiva) (1 trial)
lamivudine (epivir) (1 trial)
Acquired Immunodeficiency Syndrome (Phase 2)
HIV Infections (Phase 2)
Infections (Phase 2)
Tuberculosis (Phase 3)
Trials (17 total)
Trial APIs (26 total)